

SUPPLEMENTARY MATERIAL

Supplemental Table 1. Literature review of clinical characteristics in corticosteroid-resistant AGEP patients. RA, rheumatoid arthritis; SLE, Systemic Lupus Erythematosus; Resolution Duration (Days): time from drug start to lesion disappearance; NA, not available.

Author	Year	Age	Sex	Targetoid lesion	Delay to onset of symptoms	Primary disease	Suspect Drug	Systemic corticosteroid	Improved Treatment	Resolution Duration (Days)
Current case	2022	30	Female	Y	28	SLE	HCQ	Nonresponse	Ixekizumab	10
Yalçın[1]	2015	67	Female	Y	15	Seronegative polyarthritis	HCQ	Nonresponse	Cyclosporine with prednisolone	5
Duman[2]	2017	42	Female	Y	20	RA	HCQ	Nonresponse	Methylprednisolon and dapsone	35
Castner[3]	2018	56	Female	Y	21	Sjogren's syndrome	HCQ	Nonresponse	Cyclosporine (alone)	42
Otake-Irie[4]	2020	61	Male	Y	7	SLE	HCQ	Nonresponse	Methylprednisolone (1 g/day for 3 consecutive days)	NA
Haruna Matsuda-Hirose[5]	2020	31	Female	Y	15	SLE	HCQ	Nonresponse	Prednisolone and Etretinate	84

Coleman[6]	2020	68	Female	Y	20	Skin nodule disease	HCQ	Nonresponse	Methylprednisolone and IVIG	>10
Sánchez-Velázquez [7]	2021	43	Female	Y	9	Synovitis	HCQ	Nonresponse	Cyclosporine with Methylprednisolone	60
Meiss[8]	2007	34	Male	NA	NA	NA	ampicillin/sulbactam	Nonresponse	Infliximab	14
		49	Female	NA	NA	NA	clindamycin	Nonresponse	Infliximab	14
		43	Female	NA	NA	NA	amoxicillin	Nonresponse	Infliximab	14
Di Lerna[9]	2009	63	Female	N	30	RA	HCQ	Nonresponse	Cyclosporine (alone)	35
İslamoğlu[10]	2019	64	Female	N	20	Sjogren's syndrome	HCQ	Nonresponse	Cyclosporine (alone)	22
Gualtieri[11]	2019	63	Male	N	14	Onychomycosis	Terbinafine	Nonresponse	Secukinumab	3

Supplemental Table 2. Literature review of the clinical characteristic in corticosteroid-sensitive AGEP patients. RA, rheumatoid arthritis; SJS, Stevens-Johnson syndrome; SLE, Systemic Lupus Erythematosus; pSS, Primary Sjogren's syndrome; Resolution Duration (Days), The time from drug start to lesion disappearance; NA, not available.

Author	Year	Age	Sex	Targetoid lesion	Delay to onset of symptoms	Primary disease	Suspect Drug	Systemic corticosteroid	Improved Treatment	Resolution Duration (Days)
Martins[12]	2006	51	Female	N	14	RA	HCQ	response	Systemic steroids	21 d
Paradisi[13]	2008	36	Female	N	21	RA and pSS	HCQ	response	Systemic steroids	8 d
		70	Male	N	20	RA	HCQ	response	Systemic steroids	12
		79	Female	N	20	polymyalgia rheumatica	HCQ	response	Systemic steroids	15
Park[14]	2010	38	Female	N	20	Dermatomyositis	HCQ	response	Systemic steroids	NA
Bailey[15]	2013	48	Female	N	14	SLE	HCQ	response	Systemic steroids	18 d
Zhang[16]	2015	60	Female	N	25	pSS	HCQ	response	Systemic steroids	14 d
Enos[17]	2020	29	Female	N	4	SJS	HCQ	response	Systemic steroids	38 d
Mohaghegh [18]	2018	44	Female	Y	5	Joint pain	HCQ	response	Systemic steroids	>52
Robustelli Test[19]	2020	70	Female	Y	10	Covid-19	HCQ	response	Systemic steroids	28

Supplemental Table 3. Number of patients in HCQ-induced AGEP. The analysis was conducted by fisher's exact test.

	Corticosteroid-insensitive	Corticosteroid-sensitive
Targetoid lesions	8	2
Without targetoid lesions	2	8